Role of rituximab in the first line therapy of high risk diffuse large B cell lymphoma: a retrospective analysis by Polish Lymphoma Research Group.

CONCLUSIONS:  With all limitations of retrospective analysis, the superiority of adding rituximab to CHOP combination chemotherapy has been clearly demonstrated regarding ORR, OS and PFS in both age subgroups of patients with high risk DLBCL. PMID: 26334344 [PubMed - as supplied by publisher]
Source: Polskie Archiwum Medycyny Wewnetrznej - Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research